These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 24109591)

  • 1. The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104.
    Foehrenbacher A; Patel K; Abbattista MR; Guise CP; Secomb TW; Wilson WR; Hicks KO
    Front Oncol; 2013; 3():263. PubMed ID: 24109591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine.
    Hicks KO; Myint H; Patterson AV; Pruijn FB; Siim BG; Patel K; Wilson WR
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):560-71. PubMed ID: 17869669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spatially-resolved pharmacokinetic/pharmacodynamic modelling of bystander effects of a nitrochloromethylbenzindoline hypoxia-activated prodrug.
    Hong CR; Mehta SY; Liyanage HDS; McManaway SP; Lee HH; Jaiswal JK; Bogle G; Tercel M; Pruijn FB; Wilson WR; Hicks KO
    Cancer Chemother Pharmacol; 2021 Oct; 88(4):673-687. PubMed ID: 34245333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling.
    Foehrenbacher A; Secomb TW; Wilson WR; Hicks KO
    Front Oncol; 2013 Dec; 3():314. PubMed ID: 24409417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue Pharmacokinetic Properties and Bystander Potential of Hypoxia-Activated Prodrug CP-506 by Agent-Based Modelling.
    Jackson-Patel V; Liu E; Bull MR; Ashoorzadeh A; Bogle G; Wolfram A; Hicks KO; Smaill JB; Patterson AV
    Front Pharmacol; 2022; 13():803602. PubMed ID: 35211015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect.
    Hong CR; Wilson WR; Hicks KO
    Neoplasia; 2019 Feb; 21(2):159-171. PubMed ID: 30591421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia.
    Guise CP; Wang AT; Theil A; Bridewell DJ; Wilson WR; Patterson AV
    Biochem Pharmacol; 2007 Sep; 74(6):810-20. PubMed ID: 17645874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity.
    Singleton RS; Guise CP; Ferry DM; Pullen SM; Dorie MJ; Brown JM; Patterson AV; Wilson WR
    Cancer Res; 2009 May; 69(9):3884-91. PubMed ID: 19366798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell Cultures.
    Hong CR; Bogle G; Wang J; Patel K; Pruijn FB; Wilson WR; Hicks KO
    Front Pharmacol; 2018; 9():1013. PubMed ID: 30279659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zinc finger nuclease knock-out of NADPH:cytochrome P450 oxidoreductase (POR) in human tumor cell lines demonstrates that hypoxia-activated prodrugs differ in POR dependence.
    Su J; Gu Y; Pruijn FB; Smaill JB; Patterson AV; Guise CP; Wilson WR
    J Biol Chem; 2013 Dec; 288(52):37138-53. PubMed ID: 24196959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxia.
    Guise CP; Abbattista MR; Tipparaju SR; Lambie NK; Su J; Li D; Wilson WR; Dachs GU; Patterson AV
    Mol Pharmacol; 2012 Jan; 81(1):31-40. PubMed ID: 21984255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.
    Patterson AV; Ferry DM; Edmunds SJ; Gu Y; Singleton RS; Patel K; Pullen SM; Hicks KO; Syddall SP; Atwell GJ; Yang S; Denny WA; Wilson WR
    Clin Cancer Res; 2007 Jul; 13(13):3922-32. PubMed ID: 17606726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.
    Mowday AM; Ashoorzadeh A; Williams EM; Copp JN; Silva S; Bull MR; Abbattista MR; Anderson RF; Flanagan JU; Guise CP; Ackerley DF; Smaill JB; Patterson AV
    Biochem Pharmacol; 2016 Sep; 116():176-87. PubMed ID: 27453434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3.
    Abbattista MR; Ashoorzadeh A; Guise CP; Mowday AM; Mittra R; Silva S; Hicks KO; Bull MR; Jackson-Patel V; Lin X; Prosser GA; Lambie NK; Dachs GU; Ackerley DF; Smaill JB; Patterson AV
    Pharmaceuticals (Basel); 2021 Nov; 14(12):. PubMed ID: 34959631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.
    Abbattista MR; Jamieson SM; Gu Y; Nickel JE; Pullen SM; Patterson AV; Wilson WR; Guise CP
    Cancer Biol Ther; 2015; 16(4):610-22. PubMed ID: 25869917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
    Guise CP; Abbattista MR; Singleton RS; Holford SD; Connolly J; Dachs GU; Fox SB; Pollock R; Harvey J; Guilford P; Doñate F; Wilson WR; Patterson AV
    Cancer Res; 2010 Feb; 70(4):1573-84. PubMed ID: 20145130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-DNA adducts as biomarkers for metabolic activation of the nitro-aromatic nitrogen mustard prodrug PR-104A.
    Stornetta A; Deng KK; Danielli S; Liyanage HDS; Sturla SJ; Wilson WR; Gu Y
    Biochem Pharmacol; 2018 Aug; 154():64-74. PubMed ID: 29630868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs.
    Hicks KO; Pruijn FB; Secomb TW; Hay MP; Hsu R; Brown JM; Denny WA; Dewhirst MW; Wilson WR
    J Natl Cancer Inst; 2006 Aug; 98(16):1118-28. PubMed ID: 16912264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects.
    Hong CR; Dickson BD; Jaiswal JK; Pruijn FB; Hunter FW; Hay MP; Hicks KO; Wilson WR
    Biochem Pharmacol; 2018 Oct; 156():265-280. PubMed ID: 30134191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A.
    Gu Y; Patterson AV; Atwell GJ; Chernikova SB; Brown JM; Thompson LH; Wilson WR
    Mol Cancer Ther; 2009 Jun; 8(6):1714-23. PubMed ID: 19509245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.